Skip to main content
SpringerLink
Log in

Infliximab in Ulcerative Colitis is Associated with an Increased Risk of Postoperative Complications After Restorative Proctocolectomy

  • Original Contribution
  • Published:
Diseases of the Colon & Rectum

Abstract

Purpose

Little data exist regarding infliximab use in surgical decision making and postoperative complications in ulcerative colitis. Our goals were to determine the rate of postoperative complications in infliximab-treated ulcerative colitis patients undergoing restorative proctocolectomy and to determine whether three-stage procedures are more often necessary.

Methods

We studied a group of infliximab-treated patients and matched control subjects who underwent two-stage restorative proctocolectomy between 2000 and 2006. Postoperative complications were compared. In addition, the rate of three-stage procedures was compared between all infliximab- and noninfliximab-treated patients.

Results

A total of 523 restorative proctocolectomies were performed. In the infliximab group, there were 46 two-stage and 39 three-stage procedures. Covariate-adjusted odds of early complication for the inflixmab group was 3.54 times that of controls (P = 0.004; 95 percent confidence interval (CI), 1.51–8.31). The odds of sepsis were 13.8 times greater (P = 0.011; 95 percent CI, 1.82–105) and the odds of late complication were 2.19 times greater (P = 0.08; 95 percent CI, 0.91–5.28) for infliximab. The odds of requirement for three-stage procedures was 2.07 times greater in the infliximab group (P = 0.011; 95 percent CI, 1.18–3.63).

Conclusions

Infliximab increases the risk of postoperative complications after restorative proctocolectomy and has altered the surgical approach to ulcerative colitis. Potential benefits of infliximab should be balanced against these risks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Su C, Salzberg BA, Lewis JD, et al. Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis. Am J Gastroenterol 2002;97:2577–84.

    Article  PubMed  CAS  Google Scholar 

  2. Chey WY, Hussain A, Ryan C, Potter GD, Shah A. Infliximab for refractory ulcerative colitis. Am J Gastroenterol 2001;96:2373–81.

    Article  PubMed  CAS  Google Scholar 

  3. Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opin Biol Ther 2006;6:401–8.

    Article  PubMed  CAS  Google Scholar 

  4. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128:1805–11.

    Article  PubMed  CAS  Google Scholar 

  5. Kohn A, Prantera C, Pera A, Cosintino R, Sostegni R, Daperno M. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 2002;34:626–30.

    Article  PubMed  CAS  Google Scholar 

  6. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 2003;52:998–1002.

    Article  PubMed  CAS  Google Scholar 

  7. Sands BE, Tremaine WJ, Sandborn WJ, et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 2001;7:83–8.

    Article  PubMed  CAS  Google Scholar 

  8. Ochsenkuhn T, Sackmann M, Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 2004;16:1167–71.

    Article  PubMed  Google Scholar 

  9. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.

    Article  PubMed  CAS  Google Scholar 

  10. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878–83.

    Article  PubMed  CAS  Google Scholar 

  11. Marchal L, D’Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749–54.

    Article  PubMed  CAS  Google Scholar 

  12. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007;204:956–63.

    Article  PubMed  Google Scholar 

  13. Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. BMJ 1978;2:85–8.

    Article  PubMed  CAS  Google Scholar 

  14. Fazio VW, Ziv Y, Church JM, et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 1995;222:120–7.

    Article  PubMed  CAS  Google Scholar 

  15. Fazio VW, O’Riordain MG, Lavery IC, et al. Long-term functional outcome and quality of life after stapled restorative proctocolectomy. Ann Surg 1999;230:575–84.

    Article  PubMed  CAS  Google Scholar 

  16. Shen EH, Das KM. Current therapeutic recommendations: infliximab for ulcerative colitis. J Clin Gastroenterol 2004;38:741–5.

    Article  PubMed  CAS  Google Scholar 

  17. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the mayo clinic experience in 500 patients. Gastroenterology 2004;126:19–31.

    Article  PubMed  CAS  Google Scholar 

  18. Lichtenstein GR, Feagan B, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT regi stry. Clin Gastroenterol Hepatol 2006;4:621–30.

    Article  PubMed  CAS  Google Scholar 

  19. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96:776–81.

    Article  PubMed  CAS  Google Scholar 

  20. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic or unnecessary toys. Gut 2006;55:426–31.

    Article  PubMed  CAS  Google Scholar 

  21. Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic and therapeutic implications. Am J Gastroenterol 2004;99:938–45.

    Article  PubMed  Google Scholar 

References

  1. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76.

    Article  PubMed  CAS  Google Scholar 

  2. Strong SA, Fazio VW. Surgical treatment of inflammatory bowel disease. Curr Opin Gastroenterol 1999;15:326–30.

    Article  PubMed  CAS  Google Scholar 

  3. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment inflammatory bowel disease. Gut 2004;53:780–2.

    Article  PubMed  CAS  Google Scholar 

  4. Colombel JF, Loftus EV, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19–31.

    Article  PubMed  CAS  Google Scholar 

  5. Colombel JF, Loftus EV, Tremaine WJ, et al. Early postoperative complications were not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878–83.

    Article  PubMed  CAS  Google Scholar 

  6. Marchal L, D’Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749–54.

    Article  PubMed  CAS  Google Scholar 

  7. Brzezinski A, Amstrong L, Alvarez del Real G, et al. Infliximab does not increase the risk of complications in the peri-operative period in patients with Crohn’s disease [abstract]. Gastroenterology 2002;122:A617.

    Google Scholar 

  8. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621–30.

    Article  PubMed  CAS  Google Scholar 

  9. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007;204:956–63.

    Article  PubMed  Google Scholar 

  10. Schluender SJ, Ippoliti A, Dubinsky M, et al. Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis. Dis Colon Rectum 2007;50:1747–53.

    Article  PubMed  Google Scholar 

References

  1. Colombel JF, Loftus EV, Tremaine WJ, et al. Early postoperative complications were not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878–83.

    Article  PubMed  CAS  Google Scholar 

  2. Marchal L, D’Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749–54.

    Article  PubMed  CAS  Google Scholar 

  3. Brzezinski A, Amstrong L, Alvarez del Real G, et al. Infliximab does not increase the risk of complications in the peri-operative period in patients with Crohn’s disease [abstract]. Gastroenterology 2002;122:A617.

    Google Scholar 

  4. Selvasekar CR, Cima RR, Larson DW, et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 2007;204:956–63.

    Article  PubMed  Google Scholar 

  5. Mack DR, Langton C, Markowitz J, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics 2007;119:113–9.

    Article  Google Scholar 

  6. Kapsoritakis AN, Koukourakis MI, Sfiridaki A, et al. Mean platelet volume: a useful marker of inflammatory bowel disease activity. Am J Gastroenterol 2001;96:776–81.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Digestive Diseases Institute, A30, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio, 44195, USA

    I. J. Mor M.D., F.R.A.C.S., J. D. Vogel M.D., A. da Luz Moreira M.D., B. Shen M.D., J. Hammel M.S. & F. H. Remzi M.D.

Authors
  1. I. J. Mor M.D., F.R.A.C.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. D. Vogel M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. da Luz Moreira M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. Shen M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Hammel M.S.
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. F. H. Remzi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. H. Remzi M.D..

Additional information

Dr. Sandborn is a consultant (fees paid to Mayo Clinic) to Centocor, Abbott Laboratories, and UCB Pharma; research support for Centocor, Abbott Laboratories, and UCB Pharma.

Dr. Pardi is a consultant to Abbott, Salix, Lonza, Elan, and Biobalance; research support for Salix, Proctor & Gamble, Astra Zeneca, Genzyme, Ocera, Optimer Pharmaceuticals, and Massachusetts Biologic Laboratories.

Supported by the Edward and Josephine Story Cleveland Clinic Ileal Pouch Database Fund.

About this article

Cite this article

Mor, I.J., Vogel, J.D., da Luz Moreira, A. et al. Infliximab in Ulcerative Colitis is Associated with an Increased Risk of Postoperative Complications After Restorative Proctocolectomy. Dis Colon Rectum 51, 1202–1210 (2008). https://doi.org/10.1007/s10350-008-9364-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10350-008-9364-7

Key words

Search

Navigation